Navigation Links
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
Date:10/11/2007

- Phase 2 monotherapy trial to be initiated by end of 2007 -

PRAGUE, Czech Republic, Oct. 11 /PRNewswire-FirstCall/ -- Biogen Idec Inc. (Nasdaq: BIIB) and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium-enhancing lesions when daclizumab is added to interferon beta therapy in patients with active relapsing multiple sclerosis (MS). These data will be presented tomorrow at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic.

The ongoing Phase 2, randomized, double blind, placebo-controlled clinical study, known as the CHOICE trial, studies MS patients who continue to have active MS disease while receiving interferon beta therapy. The study patients who received daclizumab 2 mg/kg subcutaneously every two weeks showed a statistically significant 72% reduction in the number of new or enlarged gadolinium-enhancing lesions (Gd+) at week 24, compared to patients on interferon beta therapy alone. Patients from the CHOICE study were followed for an additional 48 weeks after the daclizumab treatment period to further assess safety and efficacy.

"Patients who received daclizumab every two weeks experienced far fewer new or enlarged gadolinium-enhancing lesions than the control group, which indicates that the antibody may be a promising option for patients with MS," said Dr. Xavier Montalban, Direct
'/>"/>

SOURCE Biogen Idec Inc.
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., ,, BOCA RATON, Fla., Nov. 25 /PRNewswi...l year. Not so for BodyLogicMD. The nation,s larg...ns specializing exclusively in medically supervise... physicians in its network since November 20...s to add more physician-owned centers, including o...
(Date:11/25/2009)... Nov. 25 Ardea Bioscienc...ry D. Quart, Pharm.D., president and chief executi... Annual Health Care Conference. , ,Presentation d...Health Care Conference,Date: Tuesday, Decembe...on: The New York Palace Hotel, New York, NY,Webca...
(Date:11/24/2009)... The New York investment bank KTA Capital,s clie... an AU$6.7 mil convertible note private placement ...acement was arranged by KTA Capital as Neuren,s ex... New York (PRWEB) November 23, 2009 -...ital, LLC ("KTA Capital") has announced ...
(Date:11/24/2009)...S, Nov. 24 Sigma-Aldrich...t the NASDAQ OMX conference on Tuesday, December 1...ested parties may listen via live audio broadcast ...or.sig m a a ldrich.com/ . Users can click t...bout Sigma-Aldrich: Sigma-Aldrich is a leading L...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...g Research Institute Introduce New Research Base a... Diego , , SAN DIEGO, Feb. 11 Leading global bio...nd its affiliate Ferring Research Institute have o...ity located in Sorrento Valley, San Diego that wil...esearch and therapeutics. , , (Photo: http://w...
.... (OTC Bulletin Board: GOVX), an Atlanta-based, pu... human vaccines for diseases caused by HIV-1 (Huma...nts, today announced that Robert McNally, Ph.D., C...corporate update at the Eleventh Annual BIO CEO &a...Astoria Hotel, in New York. , , Dr. McNally prese...
...hronic Pain Indications , , LA JOLLA, Calif., Feb...TX ) today announced that oral administration of N...agonist, was safe and well-tolerated in healthy ma...ive consecutive days. , , "The successful complet... and tolerability of NGX426 when dosed over multip...
Other Biology Technology:Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 2Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 2GeoVax Update Provided at the BIO CEO & Investor Conference 2009 3GeoVax Update Provided at the BIO CEO & Investor Conference 2009 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 5First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
(Date:11/23/2009)..., CINCINNATINew research presents strong evidence...ure to both outdoor traffic-related pollution and ...ngs than one or the other exposure alone. , En... Cincinnati (UC) College of Medicine have shown th...-related particles and indoor endotoxin during ear...
(Date:11/23/2009)..., TORONTO, November 23, 2009 - The time of day ...rding to a new paper produced by a research team l...ronto Scarborough,s vice-principal for research an... biology at the St. George campus. , Capitaliz... the poplar tree, the research team examined how p...
(Date:11/23/2009)..., Farmington, CT Current research suggests that ...disease. The related report by Nichols et al, "Un...t a New Class of TLR2 Ligands Capable of Enhancing... of The American Journal of Pathology . , Multi...tem attacks the brain and spinal cord, affects nea...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Martek to Present at Upcoming Canaccord Adams Conference 52983 1Mathematical modeling predicts response to Herceptin 52980 1Mathematical modeling predicts response to Herceptin 52980 2Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 1Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 2
... CORVALLIS, Ore. Contrary to 40 years of convent...y in the journal Nature suggests that old growth...ue to absorb carbon dioxide from the atmosphere an...r, these old growth forests around the world are n...en considered of no significance in the national "...
... VIRGINIA KEY, Fla. -- The precise timing of the ...ring the past 4.5 billion years has been a subject...rincipal indicator of the amount of organic carbon...d is the ratio of the less abundant isotope of car...lants preferentially incorporate 12C, during perio...
... , Researchers studying a critical stage of pregna...e found a protein that is vital to the growth of n...this protein, which is produced in higher quantiti...kely to survive. , This is the first study to det...rogen spurs cell differentiation and blood-vessel ...
Other Biology News:Old growth forests are valuable carbon sinks 2Old growth forests are valuable carbon sinks 3University of Miami scientist uncovers miscalculation in geological undersea record 2Gap junction protein vital to successful pregnancy, researchers find 2
...ptide sequence corresponding to Tyr89 Gly265 of m...recombinant soluble proform of MT1-MMP purified fr...fic activity of MT1-MMP catalytic domain is = 140 ... mol peptide (7-methoxycoumarin-4-yl)acetyl-Pro-Le...
...current power supply capable of producing up to 50...ce for PAGE, SDS-PAGE and DNA or RNA submarine gel...ng applications.A dual function 100-hour time can ...cally accrue elapsed time when operated in the pas...
Anti-Interferon-beta (IFNb) Monoclonal Antibody, Unconjugated from CHEMICON
...100, RVT400, RVT405DDA, RVT4104 and Universal Vacu...DA., A non-corrosive, odorless specially formulat...res ranging from -105 to +260 degrees Celsius. Cry... evaporate. Far superior to dry ice and acetone.,...
Biology Products: